Euglena Co.,Ltd. launched the new product CONC Wrinkle Injection Gen2 on 26 August. The share price recently rose from a closing price of ¥351 on 19 August to ¥359 on 26 August.
The launch of the new product CONC Wrinkle Injection Gen2 on 26 August marked a period in which recent disclosure items have continued intermittently. The share price also rose 2.3%, from a closing price of ¥351 on 19 August to ¥359 on 26 August, and remained in the upper ¥350 range over the past 5 trading days.
In terms of earnings, the company announced its results on 7 August 2026 and reported a return to profitability for the interim period, with revenue of ¥26.5 billion, operating profit of ¥1.9 billion, ordinary profit of ¥1.7 billion and interim net income attributable to owners of the parent of ¥73 million. Growth in the healthcare business and an improved cost structure contributed to the result.
The earnings trend over the past 12 quarters indicates a recovery in profitability, while improvements in the equity ratio and EPS have also been highlighted. At the same time, potential risk factors that could affect future earnings have been identified, including increased advertising investment and fluctuations in the supply and demand for biofuel feedstocks.
Future growth is expected to be driven by expansion of the direct-to-consumer customer base, distribution channels and orders for OEM and raw-material products. The creation of demand following the start of HVO supply and progress on plans to build a commercial plant have also been identified as areas of focus.
Summaries of the earnings briefing materials, recent earnings trends and key points for monitoring future performance are also provided as external information. The main text includes supplementary specific figures and facts, while further reports may provide additional details.